Predictive markers in bladder cancer: Do we have molecular markers ready for clinical use?

References

• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917
   PubMed Web of Science ®Google Scholar
• Ferlay J, Randi G, Bosetti C, et al. Declining mortality from bladder cancer in Europe. BJU Int 2008;101:11–9
   PubMed Web of Science ®Google Scholar
• Abdollah F, Gandaglia G, Thuret R, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 2013;37:219–25
   PubMed Web of Science ®Google Scholar
• Messing EM. Urothelial tumors of the urinary tract. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Cambell’s Urology, 8th ed. Philadelphia: Saunders, 2004:2737
   Google Scholar
• Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009;374:239–49
   PubMed Web of Science ®Google Scholar
• McDougal WS, Shipley WU, Kaufman DS, et al. Cancer of the bladder, ureter, and renal pelvis. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 8th ed. Philadelphia: Lippincott Williams and Wilkins, 2008:1358–84
   Google Scholar
• Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010;28:409–28
   PubMed Web of Science ®Google Scholar
• Edge S, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual, 7th ed. New York: Springer-Verlag, 2010:497–505
   Google Scholar
• Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006;68:549–53
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Zigeuner R, et al. Guidelines on Non-muscle Invasive Bladder Cancer (TaT1 and CIS). European Association of Urology. 2013. Available from http://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer_LR.pdf [last accessed 4 May 2014]
   Google Scholar
• Witjes JA, Comperat E, Cowan NC, et al. Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. European Association of Urology. 2013. Available from http://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer_LR.pdf [last accessed 4 May 2014]
   Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–77
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette–Guerin: the CUETO scoring model. J Urol 2009;182:2195–203
   PubMed Web of Science ®Google Scholar
• Van Rhijn BW, Zuiverloon TC, Vis AN, et al. Molecular grade (FGFR3/MIB1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010;58:433–41
   PubMed Web of Science ®Google Scholar
• Fernandez-Gomez J, Madero R, Solsona E, et al; Club Urológico Español de Tratamiento Oncológico. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette–Guérin: external validation of the EORTC risk tables. Eur Urol 2011;60:423–30
   PubMed Web of Science ®Google Scholar
• Xylinas E, Kent M, Kluth L, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer 2013;109:1460–6
   PubMed Web of Science ®Google Scholar
• Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with Bacillus Calmette–Guérin. Eur Urol 2012;62:118–25
   PubMed Web of Science ®Google Scholar
• Alkhateeb SS, Neill M, Bar-Moshe S, et al. Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette–Guérin. Urol Ann 2011;3:119–26
   PubMedGoogle Scholar
• Shah JB, McConkey DJ, Dinney PN. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res 2011;17:2608–12
   PubMed Web of Science ®Google Scholar
• Knowles MA, Elder PA, Williamson M, et al. Allelotype of human bladder cancer. Cancer Res 1994;54:531–8
   PubMed Web of Science ®Google Scholar
• Tsai YC, Nichols PW, Hiti AL, et al. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res 1990;50:44–7
   PubMed Web of Science ®Google Scholar
• Lindgren D, Liedberg F, Andersson A, et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006;25:2685–96
   PubMed Web of Science ®Google Scholar
• Fadl-Elmula I, Kytola S, Pan Y, et al. Characterization of chromosomal abnormalities in uroepithelial carcinomas by G-banding, spectral karyotyping and FISH analysis. Int J Cancer 2001;92:824–31
   Google Scholar
• Houskova L, Zemanova Z, Babjuk M, et al. Molecular cytogenetic characterization and diagnostics of bladder cancer. Neoplasma 2007;54:511–6
   Google Scholar
• Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2000;54:215–21
   Google Scholar
• Kawauchi S, Sakai H, Ikemoto K, et al. 9P21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology. Hum Pathol 2009;40:1783–9
   Google Scholar
• Kruger S, Mess F, Bohle A, Feller AC. Numerical aberrations of chromosome 17 and the 9P21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 2003;23:41–8
   PubMed Web of Science ®Google Scholar
• Mhawech-Faucelia P, Cheney RT, Schwaller J. Genetic alterations in urothelial bladder carcinoma: an updated review. Cancer 2006;106:1205–16
   Google Scholar
• Olumi AF, Tsai YC, Nichols PW, et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 1990;50:7081–3
   PubMed Web of Science ®Google Scholar
• Presti JC Jr, Reuter VE, Galan T, et al. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res 1991;51:5405–9
   PubMed Web of Science ®Google Scholar
• Pycha A, Mian C, Posch B, et al. Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators? Urology 1999;53:1005–10
   Google Scholar
• Sardi I, Bartoletti R, Occhini I, et al. Microsatellite alterations in superficial and locally advanced transitional cell carcinoma of the bladder. Oncol Report 1999;6:901–5
   Google Scholar
• Kim W-J, Bae S-C. Molecular biomarkers in urothelial bladder cancer. Cancer Sci 2008;99:646–52
   PubMed Web of Science ®Google Scholar
• Vaish M, Mandhani A, Mittal RD, Mittal B. Microsatellite instability as prognostic marker in bladder tumors: a clinical significance. BMC Urol 2005;5:2. doi:10.1186/1471-2490-5-2
   PubMedGoogle Scholar
• Sarosdy MF, Kahn PR, Ziffer MD, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006;176:44–7
   PubMed Web of Science ®Google Scholar
• Maffezzini M, Campodonico F, Capponi G, et al. Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Res 2010;30:4761–5
   PubMedGoogle Scholar
• Gofrit ON, Zorn KC, Silvestre J, et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 2008;26:246–9
   PubMed Web of Science ®Google Scholar
• Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette–Guerin therapy. Int J Cancer 2009;124:2899–904
   PubMedGoogle Scholar
• Whitson J, Berry A, Carroll P, Konety B. A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 2009;104:336–9
   PubMedGoogle Scholar
• Mian C, Lodde M, Comploj E, et al. Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol 2006;59:984–7
   Google Scholar
• Cheng L, Zhang S, MacLennan GT, et al. Bladder cancer: translating molecular genetic insights into clinical practice. Hum Pathol 2011;42:455–81
   PubMed Web of Science ®Google Scholar
• Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005;5:713–25
   PubMed Web of Science ®Google Scholar
• Rotterud R, Nesland JM, Berner A, Fossa SD. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int 2005;95:1344–50
   PubMed Web of Science ®Google Scholar
• Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001;158:1955–9
   PubMed Web of Science ®Google Scholar
• Bolenz C, Shariat SF, Karakiewicz PI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 2010;106:1216–22
   PubMed Web of Science ®Google Scholar
• Eissa S, Ali HS, Al Tonsi AH, et al. HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochem 2005;38:142–8
   Web of Science ®Google Scholar
• Gandour-Edwards R, Lara PN Jr, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002;95:1009–15
   PubMed Web of Science ®Google Scholar
• Latif Z, Watters AD, Dunn I, et al. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer 2004;40:56–63
   PubMed Web of Science ®Google Scholar
• Leibl S, Zigeuner R, Hutterer G, Chromecki T, et al. EGFR expression in urothelial carcinoma of the upper urinary tract is associated with disease progression and metaplastic morphology. APMIS 2008;116:27–32
   PubMed Web of Science ®Google Scholar
• Mason RA, Morlock EV, Karagas MR, et al. EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis 2009;30:1155–60
   Google Scholar
• Simonetti S, Russo R, Ciancia G, et al. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol 2009;17:198–205
   PubMed Web of Science ®Google Scholar
• Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007;25:581–93
   PubMed Web of Science ®Google Scholar
• Zuiverloon TC, van der Aa MN, van der Kwast TH, et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res 2010;16:3011–8
   PubMed Web of Science ®Google Scholar
• Miyake M, Sugano K, Sugino H, et al. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer. Cancer Sci 2010;101:250–8
   PubMed Web of Science ®Google Scholar
• Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006;24:3664–71
   PubMed Web of Science ®Google Scholar
• Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010;5:e13821
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265–8
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912–21
   PubMed Web of Science ®Google Scholar
• Dyrskjot L, Zieger K, Kruhoffer M, et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005;11:4029–36
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, van der Kwast TH, Vis AN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004;64:1911–4
   PubMed Web of Science ®Google Scholar
• Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108–12
   PubMed Web of Science ®Google Scholar
• Wallerand H, Bakkar AA, de Medina SG, et al. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis 2005;26:177–84
   PubMed Web of Science ®Google Scholar
• Park J, Song C, Shin E, et al. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with Bacillus Calmette–Guerin intravesical therapy? Urol Oncol 2013;31:849–56
   PubMed Web of Science ®Google Scholar
• Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal 2000;1:12–21
   Google Scholar
• Wells A. The epidermal growth factor receptor (EGFR) – a new target in cancer therapy. Signal 2000;1:4–11
   Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241–50
   PubMed Web of Science ®Google Scholar
• Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985;1:366–8
   PubMed Web of Science ®Google Scholar
• Villares GJ, Zigler M, Blehm K, et al. Targeting EGFR in bladder cancer. World J Urol 2007;25:573–9
   PubMedGoogle Scholar
• Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990;50:2530–7
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol 1994;101:166–76
   PubMed Web of Science ®Google Scholar
• Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, P53) expression and long-term prognosis. Br J Cancer 1994;69:1120–5
   PubMed Web of Science ®Google Scholar
• Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol 1995;153:919–25
   PubMed Web of Science ®Google Scholar
• Ravery V, Grignon D, Angulo J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 1997;25:9–17
   PubMed Web of Science ®Google Scholar
• Liukkonen T, Rajala P, Raitanen M, et al. Prognostic value of MIB1 score, P53, EGFr, mitotic index and papillary status in primary superficial (Stage pTa/T1) bladder cancer: a prospective comparative study. Eur Urol 1999;36:393–400
   PubMed Web of Science ®Google Scholar
• Popov Z, Gil-Diez-De-Medina S, Ravery V, et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 2004;22:93–101
   PubMed Web of Science ®Google Scholar
• Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002;7:2–8
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003;46(Suppl):S85–104
   Google Scholar
• Kassouf W, Luongo T, Brown G, et al. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 2006;176:787–92
   PubMed Web of Science ®Google Scholar
• Philips GK, Halabi S, Sanford BL, et al; Cancer and Leukaemia Group B. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int 2008;101:20–5
   PubMed Web of Science ®Google Scholar
• Lipponen P, Eskelinen M, Syrjanen S, et al. Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 1991;20:238–42
   PubMed Web of Science ®Google Scholar
• Lae M, Couturier J, Oudard S, et al. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010;21:815–9
   PubMed Web of Science ®Google Scholar
• Fleischmann A, Rotzer D, Seiler R, et al. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 2011;60:350–7
   PubMed Web of Science ®Google Scholar
• Sato K, Moriyama M, Mori S, et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992;70:2493–8
   PubMed Web of Science ®Google Scholar
• Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Ther 2010;10:407–15
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005;62:309–17
   PubMedGoogle Scholar
• Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7:2440–7
   PubMed Web of Science ®Google Scholar
• Kruger S, Weitsch G, Buttner H, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002;102:514–8
   PubMed Web of Science ®Google Scholar
• Kolla SB, Seth A, Singh MK, et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2008;40:321–7
   PubMed Web of Science ®Google Scholar
• Kruger S, Weitsch G, Buttner H, et al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 2002;21:981–7
   PubMed Web of Science ®Google Scholar
• Kassouf W, Black PC, Tuziak T, et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 2008;179:353–8
   PubMed Web of Science ®Google Scholar
• Mellon JK, Lunec J, Wright C, et al. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996;155:321–6
   Web of Science ®Google Scholar
• Chow NH, Chan SH, Tzai TS, et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7:1957–62
   PubMed Web of Science ®Google Scholar
• Liedberg F, Anderson H, Chebil G, et al. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 2008;26:17–24
   PubMed Web of Science ®Google Scholar
• Underwood M, Bartlett J, Reeves J, et al. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res 1995;55:2422–30
   PubMed Web of Science ®Google Scholar
• Hussain M, Smith DC, Al-Sukhun S, et al. Preliminary results of HER-2/neu screening and treatment with trastuzumab (Herceptin) (T), paclitaxel (P), carboplatin (C) and gemcitabine (G) in patients with advanced urothelial cancer. In: Proceedings of the American Society of Clinical Oncology, 38th Annual Meeting, 2002. May 18–21. Abstract no. 800
   Google Scholar
• Hussain MH, MacVicar GR, Petrylak DP, et al; National Cancer Institute. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007;25:2218–24
   PubMed Web of Science ®Google Scholar
• Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6:678–86
   PubMed Web of Science ®Google Scholar
• Esrig D, Spruck CH III, Nichols PW, et al. P53 nuclear protein accumulation correlates with mutations in the P53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389–97
   PubMed Web of Science ®Google Scholar
• Watanabe J, Nishiyama H, Okubo K, et al. Clinical evaluation of P53 mutations in urothelial carcinoma by IHC and FASAY. Urology 2004;63:989–93
   Google Scholar
• McShane LM, Aamodt R, Cordon-Cardo C, et al. Reproducibility of P53 immunohistochemistry in bladder tumors. National Cancer Institute, Bladder Tumor Marker Network. Clin Cancer Res 2000;6:1854–64
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388–92
   PubMed Web of Science ®Google Scholar
• Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear P53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259–64
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of P53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995;13:1384–90
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of P53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53–9
   PubMed Web of Science ®Google Scholar
• Garcia del Muro X, Condom E, Vigues F, et al. P53 and P21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004;100:1859–67
   PubMedGoogle Scholar
• Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (P53, P21Waf1, P27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 2004;45:606–12
   PubMed Web of Science ®Google Scholar
• Tzai TS, Tsai YS, Chow NH. The prevalence and clinicopathologic correlate of P16INK4a, retinoblastoma and P53 immunoreactivity in locally advanced urinary bladder cancer. Urol Oncol 2004;22:112–8
   PubMed Web of Science ®Google Scholar
• Shariat SF, Bolenz C, Karakiewicz PI, et al. P53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int 2010;105:489–95
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Parekh DJ, Ben-Porat L, et al. Prospective evaluation of P53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 2007;99:281–5
   PubMed Web of Science ®Google Scholar
• Ecke TH, Sachs MD, Lenk SV, et al. TP53 gene mutations as an independent marker for urinary bladder cancer progression. Int J Mol Med 2008;21:655–61
   Google Scholar
• Esrig D, Elmajian D, Groshen S, et al. P53 and the treatment of bladder cancer. Nature 1997;385:123–4
   Google Scholar
• Fleshner N, Kapusta L, Ezer D, et al. P53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. J Urol 2000;164:1177–82
   PubMed Web of Science ®Google Scholar
• Lipponen PK. Overexpression of P53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993;53:365–70
   PubMed Web of Science ®Google Scholar
• Lianes P, Charytonowicz E, Cordon-Cardo C, et al. Biomarker study of primary nonmetastatic versus metastatic invasive bladder cancer. National Cancer Institute Bladder Tumor Marker Network. Clin Cancer Res 1998;4:1267–71
   PubMed Web of Science ®Google Scholar
• Schmitz-Draüger BJ, Goebell PJ, Ebert T, Fradet Y. P53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 2000;38:691–9; discussion 700
   Google Scholar
• Tokunaga H, Shariat SF, Green AE, et al. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys 2001;51:16–22
   PubMed Web of Science ®Google Scholar
• Schrier BP, Vriesema JLJ, Witjes JA, et al. The predictive value of P53, P27Kip1, and a-catenin for progression in superficial bladder carcinoma. Eur Urol 2006;50:76–82
   Google Scholar
• Goebell PJ, Groshen SG, Schmitz-Drager BJ. P53 immunohistochemistry in bladder cancer – a new approach to an old question. Urol Oncol 2010;28:377–88
   Google Scholar
• Bolenz C, Lotan Y. Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nat Clin Pract Urol 2008;5:676–85
   PubMedGoogle Scholar
• Llopis J, Alcaraz A, Ribal MJ, et al. P53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol 2000;37:644–53
   PubMed Web of Science ®Google Scholar
• Rodriguez-Alonso A, Pita-Fernandez S, Gonzalez-Carrero J, Nogueira-March JL. P53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 2002;41:182–8; discussion 188–9
   PubMed Web of Science ®Google Scholar
• Shariat SF, Bolenz C, Godoy G, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009;182:78–84
   PubMed Web of Science ®Google Scholar
• Shariat SF, Zlotta AR, Ashfaq R, et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007;20:445–59
   PubMed Web of Science ®Google Scholar
• Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007;177:481–7; discussion 487
   PubMed Web of Science ®Google Scholar
• Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006;37:1568–76
   PubMed Web of Science ®Google Scholar
• Shariat SF, Lotan Y, Karakiewicz PI, et al. P53 Predictive value for pT1–2 N0 disease at radical cystectomy. J Urol 2009;182:907–13
   PubMedGoogle Scholar
• Dahse R, Gartner D, Werner W, et al. P53 mutations as an identification marker for the clonal origin of bladder tumors and its recurrences. Oncol Rep 2003;10:2033–7
   Google Scholar
• Suttmann H, Riemensberger J, Bentien G, et al. Neutrophil granulocytes are required for effective Bacillus Calmette–Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Res 2006;66:8250–7
   PubMed Web of Science ®Google Scholar
• Kaempfer R, Gerez L, Farbstein H, et al. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 1996;14:1778–86
   PubMed Web of Science ®Google Scholar
• Zlotta AR, Noel JC, Fayt I, et al. Correlation and prognostic significance of P53, P21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with Bacillus Calmette–Guerin intravesical therapy. J Urol 1999;161:792–8
   PubMed Web of Science ®Google Scholar
• Saint F, Le Frere Belda M-A, Quintela R, et al. Pretreatment P53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette–Guerin (BCG). Eur Urol 2004;45:475–82
   PubMed Web of Science ®Google Scholar
• Peyromaure M, Weibing S, Sebe P, et al. Prognostic value of P53 overexpression in T1G3 bladder tumors treated with Bacillus Calmette–Guerin therapy. Urology 2002;59:409–13
   PubMed Web of Science ®Google Scholar
• Moonen PM, van Balken-Ory B, Kiemeney LA, et al. Prognostic value of P53 for high risk superficial bladder cancer with long-term followup. J Urol 2007;177:80–3
   PubMed Web of Science ®Google Scholar
• Lacombe L, Dalbagni G, Zhang ZF, et al. Overexpression of P53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette–Guérin therapy: correlation to clinical outcome. J Clin Oncol 1996;14:2646–52
   PubMed Web of Science ®Google Scholar
• Palou J, Algaba F, Vera I, et al. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance Bacillus Calmette–Guerin. Eur Urol 2009;56:829–36
   PubMed Web of Science ®Google Scholar
• Esuvaranathan K, Chiong E, Thamboo TP, et al. Predictive value of P53 and PRB expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007;109:1097–105
   PubMed Web of Science ®Google Scholar
• Lebret T, Becette V, Barbagelatta M, et al. Correlation between P53 over expression and response to Bacillus Calmette–Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol 1998;159:788–91
   PubMed Web of Science ®Google Scholar
• George B, Datar RH, Wu L, et al. P53 gene and protein status: the role of P53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007;25:5352–8
   PubMed Web of Science ®Google Scholar
• De Boer EC, Rooijakkers SJ, Schamhart DH, Kurth KH. Cytokine gene expression in a mouse model: the first instillations with viable Bacillus Calmette–Guerin determine the succeeding Th1 response. J Urol 2003;170:2004–8
   Google Scholar
• Kakehi Y, Ozdemir E, Habuchi T, et al. Absence of P53 overexpression and favorable response to cisplatin-based neo-adjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer Res 1998;89:214–20
   Google Scholar
• Jankevicius F, Goebell P, Kushima M, et al. P21 and P53 immunostaining and survival following systemic chemotherapy for urothelial cancer. Urol Int 2002;69:174–80
   Google Scholar
• Cote RJ, Esrig D, Groshen S, et al. P53 and treatment of bladder cancer. Nature 1997;385:123–5
   PubMed Web of Science ®Google Scholar
• Sengelov L, Horn T, Steven K. P53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer. J Cancer Res Clin Oncol 1997;123:565–70
   PubMedGoogle Scholar
• Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on P53 status. J Clin Oncol 2011;29:3443–9
   PubMed Web of Science ®Google Scholar
• Ogura K, Habuchi T, Yamada H, et al. Immunohistochemical analysis of P53 and proliferating cell nuclear antigen (PCNA) in bladder cancer positive immunostaining and radiosensitivity. Int J Urol 1995;2:302–8
   Google Scholar
• Osen I, Fossa SD, Majak B, et al. Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. Br J Urol 1998;81:862–9
   Google Scholar
• Pollack A, Wu CS, Czerniak B, et al. Abnormal BCL-2 and PRB expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 1997;3:1823–9
   PubMedGoogle Scholar
• Rotterud R, Berner A, Holm R, et al. P53, P21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder. BJU Int 2001;88:202–8
   Google Scholar
• Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent PRB expression is associated with bladder cancer progression and has cooperative effects with P53. Cancer Res 1998;58:1090–4
   PubMed Web of Science ®Google Scholar
• Cormio L, Tolve I, Annese P, et al. Retinoblastoma protein expression predicts response to Bacillus Calmette–Guerin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol 2010;28:285–9
   Google Scholar
• Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251–6
   PubMed Web of Science ®Google Scholar
• Lee K, Jung ES, Choi YJ, et al. Expression of PRB, P53, P16 and cyclin D1 and their clinical implications in urothelial carcinoma. J Korean Med Sci 2010; 25:1449–55
   Google Scholar
• Logothetis CJ, Xu HJ, Ro JY, et al. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992;84:1256–61
   PubMed Web of Science ®Google Scholar
• Cormio L, Tolve I, Annese P, et al. Altered P53 and PRB expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res 2009;29:4201–4
   Web of Science ®Google Scholar
• Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 2008;18:1–8
   PubMed Web of Science ®Google Scholar
• Harada K, Ogden GR. An overview of the cell cycle arrest protein, P21(WAF1). Oral Oncol 2000;36:3–7
   PubMed Web of Science ®Google Scholar
• Lipponen P, Aaltomaa S, Eskelinen M, et al. Expression of P21(waf1/cip1) protein in transitional cell bladder tumours and its prognostic value. Eur Urol 1998;34:237–43
   Google Scholar
• Shariat SF, Kim J, Raptidis G, et al. Association of P53 and P21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003;61:1140–5
   PubMed Web of Science ®Google Scholar
• Migaldi M, Sgambato A, Garagnani L, et al. Loss of P21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res 2000;6:3131–8
   PubMed Web of Science ®Google Scholar
• Liukkonen T, Lipponen P, Raitanen M, et al. Evaluation of P21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol Res 2000;28:285–92
   PubMed Web of Science ®Google Scholar
• Stein JP, Ginsberg DA, Grossfeld GD, et al. Effect of P21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072–9
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI, Ashfaq R, et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112:315–25
   PubMed Web of Science ®Google Scholar
• Shariat SF, Chade DC, Karakiewicz PI, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010;183:68–75
   PubMed Web of Science ®Google Scholar
• Korkolopoulou P, Christodoulou P, Konstantinidou AE, et al. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on P27Kip1. Hum Pathol 2000;31:751–60
   PubMed Web of Science ®Google Scholar
• Sgambato A, Migaldi M, Faraglia B, et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 1999;59:3245–50
   PubMed Web of Science ®Google Scholar
• Kamai T, Takagi K, Asami H, et al. Decreasing of P27(Kip1) and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001;84:1242–51
   PubMed Web of Science ®Google Scholar
• Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000;157:787–94
   PubMed Web of Science ®Google Scholar
• Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle regulators P27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999;155:1129–36
   PubMed Web of Science ®Google Scholar
• Wagner U, Suess K, Luginbuhl T, et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol 1999;188:44–50
   Google Scholar
• Lopez-Beltran A, Requena MJ, Luque RJ, et al. Cyclin D3 expression in primary Ta/T1 bladder cancer. J Pathol 2006;209:106–13
   Google Scholar
• Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of P53, P21, and PRB expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007–13
   PubMed Web of Science ®Google Scholar
• Grossman HB, Liebert M, Antelo M, et al. P53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998;4:829–34
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of P53 and PRB alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217–21
   PubMed Web of Science ®Google Scholar
• Benedict WF, Lerner SP, Zhou J, et al. Level of retinoblastoma protein expression correlates with P16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999;18:1197–203
   PubMed Web of Science ®Google Scholar
• Jin JO, Lehmann J, Taxy J, et al. Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Cancer 2006;5:150–4
   PubMedGoogle Scholar
• Shariat SF, Tokunaga H, Zhou J, et al. P53, P21, PRB, and P16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004;22:1014–24
   PubMed Web of Science ®Google Scholar
• Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941–53
   PubMed Web of Science ®Google Scholar
• Smith SD, Wheeler MA, Plescia J, et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324–8
   PubMed Web of Science ®Google Scholar
• Shariat SF, Casella R, Khoddami SM, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171:626–30
   PubMed Web of Science ®Google Scholar
• Schultz IJ, Kiemeney LA, Karthaus HF, et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 2004;50:1425–8
   Google Scholar
• Shariat SF, Ashfaq R, Karakiewicz PI, et al. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007;109:1106–13
   PubMed Web of Science ®Google Scholar
• Schultz IJ, Kiemeney LA, Witjes JA, et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003;23:3327–31
   Google Scholar
• Karam JA, Lotan Y, Karakiewicz PI, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8:128–36
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI, Godoy G, et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res 2009;15:7012–9
   PubMed Web of Science ®Google Scholar
• Karam JA, Lotan Y, Ashfaq R, et al. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 2007;70:482–6
   PubMed Web of Science ®Google Scholar
• Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008;26:59–65
   PubMed Web of Science ®Google Scholar
• Kong G, Shin KY, Oh YH, et al. BCL-2 and P53 expressions in invasive bladder cancers. Acta Oncol 1998;37:715–20
   PubMed Web of Science ®Google Scholar
• Stavropoulos NE, Filiadis I, Ioachim E, et al. Prognostic significance of P53, BCL-2 and Ki-67 in high risk superficial bladder cancer. Anticancer Res 2002;22:3759–64
   Google Scholar
• Shiina H, Igawa M, Urakami S, et al. Immunohistochemical analysis of BCL-2 expression in transitional cell carcinoma of the bladder. J Clin Pathol 1996;49:395–9
   PubMedGoogle Scholar
• Rodel C, Grabenbauer GG, Rodel F, et al. Apoptosis, P53, BCL-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. Int J Radiat Oncol Biol Phys 2000;46:1213–21
   PubMed Web of Science ®Google Scholar
• Ong F, Moonen LM, Gallee MP, et al. Prognostic factors in transitional cell cancer of the bladder: an emerging role for BCL-2 and P53. Radiother Oncol 2001;61:169–75
   PubMed Web of Science ®Google Scholar
• Burton PB, Anderson CJ, Corbishly CM. Caspase 3 and P27 as predictors of invasive bladder cancer. N Engl J Med 2000;343:1418–20
   Google Scholar
• Svatek RS, Herman MP, Lotan Y, et al. Soluble Fas-A promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006;106:1701–7
   PubMed Web of Science ®Google Scholar
• Giannopoulou I, Nakopoulou L, Zervas A, et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res 2002;30:342–5
   Google Scholar
• Yamana K, Bilim V, Hara N, et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005;93:544–51
   PubMed Web of Science ®Google Scholar
• Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603–12
   PubMed Web of Science ®Google Scholar
• Bochner BH, Esrig D, Groshen S, et al. Relationship of tumor angiogenesis and nuclear P53 accumulation in invasive bladder cancer. Clin Cancer Res 1997;3:1615–22
   Web of Science ®Google Scholar
• Youssef RF, Mitra AP, Bartsch G Jr, et al. Molecular targets and targeted therapies in bladder cancer management. World J Urol 2009; 27:9–20
   PubMedGoogle Scholar
• Grossfeld GD, Ginsberg DA, Stein JP, et al. Thrombospondin-1 expression in bladder cancer: association with P53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89:219–27
   PubMed Web of Science ®Google Scholar
• Inoue K, Slaton JW, Karashima T, et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000;6:4866–73
   PubMed Web of Science ®Google Scholar
• Streeter EH, Harris AL. Angiogenesis in bladder cancer – prognostic marker and target for future therapy. Surg Oncol 2002;11:85–100
   PubMedGoogle Scholar
• Shariat SF, Youssef RF, Gupta A, et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010;183:1744–50
   PubMed Web of Science ®Google Scholar
• Shariat SF, Karakiewicz PI. Molecular markers for bladder cancer staging and prognosis. In: Soloway M, Khoury S, eds. Bladder Cancer, 2nd ed. Paris: ICUD-EAU – Editions 21, 2012:217
   Google Scholar
• Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol 1995;154:69–71
   PubMed Web of Science ®Google Scholar
• Zu X, Tang Z, Li Y, et al. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int 2006;98:1090–3
   PubMed Web of Science ®Google Scholar
• Miyata Y, Kanda S, Ohba K, et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res 2006;12:800–6
   Google Scholar
• Crew JP, O’Brien T, Bicknell R, et al. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 1999;161:799–804
   PubMed Web of Science ®Google Scholar
• Jeon SH, Lee SJ, Chang SG. Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors. Oncol Rep 2001;8:1265–7
   Google Scholar
• Chow NH, Liu HS, Chan SH, et al. Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res 1999;19:4593–7
   Google Scholar
• Stavropoulos NE, Bouropoulos C, Ioachim IE, et al. Prognostic significance of angiogenesis in superficial bladder cancer. Int Urol Nephrol 2004;36:163–7
   Web of Science ®Google Scholar
• Elfiky AA, Rosenberg JE. Targeting angiogenesis in bladder cancer. Curr Oncol Rep 2009;11:244–9
   PubMed Web of Science ®Google Scholar
• Youssef RF, Lotan Y. Predictors of outcome of non–muscle-invasive and muscle-invasive bladder cancer. Sci World J 2011;11:369–81
   Google Scholar
• Osai WE, Ng CS, Pagliaro LC. Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs 2008;19:427–9
   PubMed Web of Science ®Google Scholar
• Watanabe H, Hori A, Seno M, et al. A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun 1991;175:229–35
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Gohji K, et al. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett 1998;123:121–6
   PubMed Web of Science ®Google Scholar
• Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by P53 regulation of thrombospondin-1. Science 1994;265:1582–4
   PubMed Web of Science ®Google Scholar
• Cohen MB, Waldman FM, Carroll PR, et al. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Pathol 1993;24:772–8
   PubMed Web of Science ®Google Scholar
• Kruger S, Mahnken A, Kausch I, Feller AC. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 2005;47:463–7
   PubMed Web of Science ®Google Scholar
• Margulis V, Lotan Y, Karakiewicz PI, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009;101:114–9
   PubMedGoogle Scholar
• Margulis V, Shariat SF, Ashfaq R, et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006;12:7369–73
   PubMed Web of Science ®Google Scholar
• Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59:83–8
   PubMed Web of Science ®Google Scholar
• Ramos D, Ruiz A, Morell L, et al. Prognostic value of morphometry in low grade papillary urothelial bladder neoplasms. Anal Quant Cytol Histol 2004;26:285–94
   Google Scholar
• Stavropoulos NE, Ioackim-Velogianni E, Hastazeris K, et al. Growth fractions in bladder cancer defined by Ki67: association with cancer grade, category and recurrence rate of superficial lesions. Br J Urol 1993;72:736–9
   Google Scholar
• Santos L, Amaro T, Costa C, et al. Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer 2003;105:267–72
   PubMed Web of Science ®Google Scholar
• Pfister C, Moore L, Allard P, et al. Predictive value of cell cycle markers P53, MDM2, P21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999;5:4079–84
   PubMed Web of Science ®Google Scholar
• Gontero P, Casetta G, Zitella A, et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000;38:287–96
   PubMed Web of Science ®Google Scholar
• Lebret T, Becette V, Hervé J-M, et al. Prognostic value of MIB1 antibody labeling index to predict response to Bacillus Calmette–Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 2000;37:654–9
   Google Scholar
• Behnsawy HM, Miyake H, Abdalla MA, et al. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection. Urol Oncol 2011; 29:495–501
   PubMed Web of Science ®Google Scholar
• Clairotte A, Lascombe I, Fauconnet S, et al. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 2006;125:119–26
   PubMed Web of Science ®Google Scholar
• Bryan RT, Atherfold PA, Yeo Y, et al. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol 2008;215:184–94
   Google Scholar
• Jang TJ, Cha WH, Lee KS. Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas. Virchows Arch 2010;457:319–28
   PubMed Web of Science ®Google Scholar
• Koksal IT, Ates M, Danisman A, et al. Reduced E-cadherin and alpha-catenin expressions have no prognostic role in bladder carcinoma. Pathol Oncol Res 2006; 12:13–9
   Google Scholar
• Bringuier PP, Umbas R, Schaafsma HE, et al. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993;53:3241–5
   PubMed Web of Science ®Google Scholar
• Syrigos KN, Harrington K, Waxman J, et al. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J Urol 1998;160:1889–93
   PubMed Web of Science ®Google Scholar
• Byrne RR, Shariat SF, Brown R, et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001;165:1473–9
   Google Scholar
• Mhawech-Fauceglia P, Fischer G, Beck A, et al. Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 2006;32:439–44
   PubMed Web of Science ®Google Scholar
• Lascombe I, Clairotte A, Fauconnet S, et al. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res 2006;12:2780–7
   PubMed Web of Science ®Google Scholar
• Kashibuchi K, Tomita K, Schalken JA, et al. The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. Int J Urol 2007;14:789–94
   Google Scholar
• Nonomura N, Nakai Y, Nakayama M, et al. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer. Int J Clin Oncol 2006;11:297–302
   Google Scholar
• Aoki S, Yamada Y, Nakamura K, et al. Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer. Oncol Rep 2006;16:279–84
   PubMed Web of Science ®Google Scholar
• Comperat E, Camparo P, Haus R, et al. Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows Arch 2007;450:419–24
   Google Scholar
• Bufo P, Sanguedolce F, Tortorella S, et al. Expression of mitotic kinases phospho-aurora A and aurora B correlates with clinical and pathological parameters in bladder neoplasms. Histol Histopathol 2010;25:1371–7
   Google Scholar
• Shirahama T, Arima J, Akiba S, Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 2001;92:188–93
   PubMed Web of Science ®Google Scholar
• Shariat SF, Kim JH, Ayala GE, et al. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 2003;169:938–42
   PubMed Web of Science ®Google Scholar
• Kim SI, Kwon SM, Kim YS, Hong SJ. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology 2002;60:816–21
   PubMedGoogle Scholar
• Xylinas E, Kluth LA, Lotan Y, et al. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. Urol Oncol 2014;32:230–42
   PubMed Web of Science ®Google Scholar
• Cheng L, Davison DD, Adams J, et al. Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol 2014;89:73–111
   PubMed Web of Science ®Google Scholar